Swixx BioPharma is designed to fully replace biopharma, OTC and medical device multinationals’
subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational
chooses not to enter, or to exit.
With over 1,000 employees and sales likely to exceed 600M Euros in 2022, Swixx BioPharma is
already the largest agent for ethical pharmaceuticals serving research-based biopharma in CEE. The
company is staffed by a unique group of access-savvy managers and medical professionals who are
dedicated to bring modern medicines to the people of CEE region. We are a service-oriented, high
quality and ethically-driven company.
Swixx BioPharma began operations in December 2014 and is registered in Baar, Switzerland. The
company has 100%-owned affiliates in Albania, Belarus, Bosnia & Herzegovina, Bulgaria, Croatia,
Czech Republic, Estonia, Greece, Hungary, Kazakhstan, Kosovo, Latvia, Lithuania, North Macedonia,
Montenegro, Poland, Romania, Russia, Serbia, Slovakia, Slovenia and Uzbekistan. Both Swixx
BioPharma senior management and owners come from a heritage of unique success in specialty
pharmaceuticals in the CEE region. Swixx BioPharma enjoys strong financial connections with banks,
hedge funds and private equity – should the need or opportunity arise, we have unsurpassed ability
to raise capital quickly and efficiently.
In its six year history, Swixx has become both CEE’s largest and fastest-growing independent agent
Registered in Baar, Switzerland, Swixx BioPharma SA commenced operations in late 2014. The
company originally served research-based biopharma in the countries of the West Balkans and the
Baltic states, but subsequently expanded beginning in 2017 to cover the larger countries of CEE
(Bulgaria, Czech, Hungary, Poland, Romania and Slovakia). The company entered Russia in October,
2019 when it took over Alexion’s Russian operations, and later, in Spring 2020 the company also
purchased a well-established Russian specialty distributor / agent of good reputation. Swixx is now
looking further afield; an affiliate in Greece has been opened in July 2021 and presence into other
countries of the Eurasian Economic Union materialized in March 2022.
Swixx BioPharma’s management are a proven, high-calibre team. Prior to building Swixx BioPharma
into a CEE juggernaut, Swixx’s founders and many members of its senior team had created and built-
up PharmaSwiss SA, which at the time it was sold (to Bausch Health Companies in 2011) was the
largest (205M Euros in sales, 850 employees) and best-regarded agents operating across CEE.
VISION & MISSION
for Medical Community & Patients
To resolve unmet medical needs in a cost effective, ethical manner
Always to align with EBM and best practice (patient focus)
To provide expertise, knowledge and rapid execution
for Industry Partners
To bring their innovative products to CEE, leveraging a patient-centric approach
To get novel products registered, launched and reimbursed at maximum permitted price
Provide security to our partners through robust systems in compliance, quality, pricing, medical
risk-management programs, and to adhere to strict territorial limitations.
To build a global specialty pharma company with over €500m in sales within 7 years
Swixx BioPharma is designed to fully replace multinationals‘ subsidiaries in countries that the
multinational companies choose not to enter, or choose to exit. We are an unavoidable partner
Portfolio and pipeline of our clients are our first and only priority and focus
Functional expertise and focus are designed to mirror our client‘s needs
We have one raison d‘etre: service to our senior Multinational Corporate Organization partners
Our DNA is dominated by a highly specialialized medicines, as well as a compliance-driven
Rare disease focus exemplified by the creation of rare disease business unit in late 2018
Swixx BioPharma’s Commitment to Corporate Social Responsibility
At Swixx BioPharma, we are devoted to the principles of business ethics, environmental responsibility
and human rights. We deem these to be among our most important values and so integrate them
into both our ongoing and strategic activities.
We strive to be environmentally conscious in our practices. Swixx BioPharma is a commercial service
organization whose primary resource is human capital, which means that most of our environmental
impact occurs in the form of emissions produced by company cars, primarily used by our 300+ field
force employees. We have therefore implemented a car policy focused on the reduction of CO2, NOx
and other air pollutant emissions produced by car engines. Further, we are consciously trying to
reduce company-sponsored air travel and we advise employees to use public transport whenever
possible. Senior management tries to exemplify these policies in their own travel planning. Further,
company policy is for all personnel, including Board members, to travel in economy class which also
reduces carbon footprint. In addition, we continually strive to minimize waste in all of our
operations. In practice, this applies, mainly to our two warehouses in Ljubljana, Slovenia and
Beograd, Serbia, and ensuring that Swixx’s myriad offices are in environmentally friendly and well-
insulated buildings that are energy efficient.
While Swixx does not have its own production facilities or research and development, we prioritize
collaboration with producers who employ green processes, foster conservation and reduce waste
throughout their manufacturing and logistic process. More than 90% of our partners made a public
commitment to reduce their environmental impact.
We have implemented measures to protect the human rights of our employees and actively support
diversity in our hiring practices. Awareness training to prevent discrimination and harassment is
included into mandatory training for new employees and regular training updates. There is a
whistleblower policy in place including anonymous reporting of potential issues. Also, a remediation
policy is implemented for identified cases of discrimination and harassment. In addition, we are also
taking active steps to ensure and monitor gender equality, including equal pay monitoring. We are
proud to report that in 2021 women represented 71% of Swixx BioPharma all employees and
52% of leadership positions (data from September 2020).
Compliance and an ethically driven corporate culture are top priority and a core identification of
Swixx BioPharma. Since our foundation we have concentrated on building robust compliance and
quality systems at the corporate level as well as in each of our countries. Swixx BioPharma's
corporate governance is designed to ensure effective operational leadership without compromising
on ethics. Therefore, the compliance organization reports to an independent board committee. Our
employees - at HQ and in our countries - are carefully selected to have demonstrated expertise.
Broadly speaking, the company only hires experienced professionals of impeccable reputation, with
an unwavering commitment to ethics & compliance.
Our compliance systems are constantly reviewed and updated to ensure alignment with the
evolution of the organization. We are regularly ISAE 3402 certified and Swixx operations are routinely
audited by multinational and biotech companies who demand the highest standards in the industry.
As we continue to build our organization, we will continue to make the Corporate Social
Responsibility a cornerstone of everything we do.
SWIXX NET SALES (EUR) GROWING AT 63% CAGR FOR THE PAST 5 YEARS
Many western healthcare companies chose not to enter these markets, but nonetheless wish to have
their products present and represented by a professional, compliant and competent regional
partner. Swixx BioPharma aims to fill this need and to bring modern medicines to the people of the
Swixx BioPharma has been
historically focused on the CEE
region but is now swiftly
expanding into other
geographies, now incluging:
Albania, Bosnia and
Bulgaria, Croatia, Czech
Republic, Estonia, Greece,
Hungary, Kazakhstan, Kosovo,
Latvia, Lithuania, Moldova,
Macedonia, Poland, Romania,
Russia, Serbia, Slovakia,
CEE region comprise 275
million people and a
pharmaceutical market of 50+
billion Euros. Their economies
currently are amongst the
least developed in Europe, but
they show considerable
promise and boast well-
educated and cultured people.